Lasley Robert D, Keith Byron J, Kristo Gentian, Yoshimura Yukihiro, Mentzer Robert M
Department of Surgery, Univ. of Kentucky College of Medicine, MN276, Chandler Medical Center, 800 Rose St., Lexington, KY 40536-0298, USA.
Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H785-91. doi: 10.1152/ajpheart.01008.2004. Epub 2005 Apr 15.
Adenosine A1 receptor delayed preconditioning (PC) against myocardial infarction has been well described; however, there have been limited investigations of the signaling mechanisms that mediate this phenomenon. In addition, there are multiple conflicting reports on the role of inducible nitric oxide synthase (iNOS) in mediating A1 late-phase PC. The purpose of this study was to determine the roles of the p38 and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinases (MAPKs) in in vivo delayed A1 receptor PC and whether this protection at the myocyte level is due to upregulation of iNOS. Myocardial infarct size was measured in open-chest anesthetized rats 24 h after treatment with vehicle or the adenosine A1 agonist 2-chloro-N6-cyclopentyladenosine (CCPA; 100 microg/kg ip). Additional rats receiving CCPA were pretreated with the p38 inhibitor SB-203580 (1 mg/kg ip) or the MAPK/ERK kinase (MEK) inhibitor PD-098059 (0.5 mg/kg ip). At 24 h after CCPA administration, a group of animals was given the iNOS inhibitor 1400 W 10 min before ischemia. Treatment with CCPA reduced infarct size from 48 +/- 2 to 28 +/- 2% of the area at risk, an effect that was blocked by both SB-203580 and PD-098059 but not 1400 W. Ventricular myocytes isolated 24 h after CCPA injection exhibited significantly reduced oxidative stress during H2O2 exposure compared with myocytes from vehicle-injected animals, and this effect was not blocked by the iNOS inhibitor 1400 W. Western blot analysis of whole heart and cardiac myocyte protein samples revealed no expression of iNOS 6 or 24 h after CCPA treatment. These results indicate that adenosine A1 receptor delayed PC in rats is mediated by MAPK-dependent mechanisms, but this phenomenon is not associated with the early or late expression of iNOS.
腺苷A1受体延迟预处理(PC)对心肌梗死的保护作用已有详尽描述;然而,介导此现象的信号传导机制研究却很有限。此外,关于诱导型一氧化氮合酶(iNOS)在介导A1晚期PC中的作用,存在多种相互矛盾的报道。本研究旨在确定p38和细胞外信号调节激酶(ERK)丝裂原活化蛋白激酶(MAPK)在体内延迟A1受体PC中的作用,以及这种在心肌细胞水平的保护作用是否归因于iNOS的上调。在用溶媒或腺苷A1激动剂2-氯-N6-环戊基腺苷(CCPA;100μg/kg腹腔注射)处理24小时后,测量开胸麻醉大鼠的心肌梗死面积。额外接受CCPA的大鼠预先用p38抑制剂SB-203580(1mg/kg腹腔注射)或MAPK/ERK激酶(MEK)抑制剂PD-098059(0.5mg/kg腹腔注射)处理。在给予CCPA 24小时后,一组动物在缺血前10分钟给予iNOS抑制剂1400W。用CCPA治疗可使梗死面积从危险区域面积的48±2%降至28±2%,SB-203580和PD-098059均可阻断此效应,但1400W不能。与注射溶媒的动物的心肌细胞相比,CCPA注射24小时后分离的心室肌细胞在H2O2暴露期间表现出氧化应激显著降低,且iNOS抑制剂1400W不能阻断此效应。对全心和心肌细胞蛋白样品进行蛋白质印迹分析显示,CCPA处理6或24小时后未检测到iNOS表达。这些结果表明,大鼠体内腺苷A1受体延迟PC由MAPK依赖性机制介导,但此现象与iNOS的早期或晚期表达无关。